Drug Profile
Trastuzumab biosimilar - AryoGen Pharmed
Alternative Names: AryoTrustLatest Information Update: 15 Jan 2022
Price :
$50
*
At a glance
- Originator AryoGen Biopharma
- Developer AryoGen Pharmed
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; ERBB 2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Gastric cancer; HER2 positive breast cancer
Most Recent Events
- 01 Apr 2021 Phase-I clinical trials in HER2-positive-breast-cancer (In volunteers) in India (IV) (CTRI2019-03-018218)
- 26 Sep 2019 AryoGen Pharmed plans a comparative pharmacokinetics clinical trial in Healthy volunteers in India (CTRI2019-03-018218)
- 05 Aug 2018 AryoGen Pharmed completes a phase III trial in HER2-positive-breast-cancer (Late-stage disease, Inoperable/Unresectable) in Iran (IV) (IRCT201606226135N7) (NCT03425656)